Myriad Genetics, Inc.
As of Oct 22, 2026, Myriad Genetics is in Stage 4, the downtrend phase, now in week 10 (since Aug 18, 2026). It closed at $5.76, 29.6% below its 52-week high and above its 200-day average, which is falling.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MYGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MYGN among Diagnostics & Research34th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …34 | MYGN | Stage 4 · wk 10 | 34 | +43.6% |
Myriad Genetics: quick answers
What stage is Myriad Genetics in?
As of Oct 22, 2026, Myriad Genetics (MYGN) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 18, 2026 and is in week 10. What the four stages mean
Is Myriad Genetics in an uptrend?
No. Myriad Genetics is in a Stage 4 downtrend. It trades 24.8% above its 200-day average, which is falling.
How far is Myriad Genetics from its 52-week high?
Myriad Genetics closed at $5.76 on Oct 22, 2026, 29.6% below its 52-week high of $8.18. Its 52-week low is $2.86.
How has Myriad Genetics performed over the past year?
As of Oct 22, 2026, Myriad Genetics is down 28.5% over the past year and down 6.2% so far in 2026.
Which sector and industry is Myriad Genetics in?
Myriad Genetics is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.